American Heart Association Endorses NPPA for Its Stent Price Ceiling Policy

Published On 2017-05-09 06:53 GMT   |   Update On 2017-05-09 06:53 GMT

New Delhi: While the move of the NPPA of capping the price of cardiac stents  has become a topic of debate for many in the country, it seems to have found a major mention with one of the biggest Associations of Cardiologists in the world, the American Heart AssociationIn a recent research published American Heart Association's Journal Circulation, the paper titled  "India and...

Login or Register to read the full article

New Delhi: While the move of the NPPA of capping the price of cardiac stents  has become a topic of debate for many in the country, it seems to have found a major mention with one of the biggest Associations of Cardiologists in the world, the American Heart Association


In a recent research published American Heart Association's Journal Circulation, the paper titled  "India and the Coronary Stent Market-Getting the Price Right" claimed that stents prices in India are higher than US. Praising the National Pharmaceutical Pricing Authority's decision on stents price capping by 85 percent, the paper called it a corrective measure.


Comparing the prices of coronary stents in India and US, the the paper pointed out that while prices of drug-eluting stents vary between 600 dollars and 2,971 dollars in India, it is sold at around 1,200 dollars in the US


The paper also highlighted that the move is going to benefit domestic manufacturers.“Foreign firms constitute majority of the stent market. The new price regulation might allow domestic stents to claim a larger pie and cultivate production,” the report added.


You can read the article by clicking on the following link


https://circ.ahajournals.org/content/early/2017/05/04/CIRCULATIONAHA.117.028191

Medical dialogues team had earlier reported that while capping the prices of stents, the government through National Pharmaceutical Pricing Authority (NPPA) also invoked special powers under the law to prohibit stent makers from withdrawing their products from the market for the next six months and directed them to  maintain production, import and supply of coronary stents to avoid any shortage.


Read also: Government Prohibits Stent companies to withdraw stents for Next Six Months

 
Tags:    

Disclaimer: This site is primarily intended for healthcare professionals. Any content/information on this website does not replace the advice of medical and/or health professionals and should not be construed as medical/diagnostic advice/endorsement/treatment or prescription. Use of this site is subject to our terms of use, privacy policy, advertisement policy. © 2024 Minerva Medical Treatment Pvt Ltd

Our comments section is governed by our Comments Policy . By posting comments at Medical Dialogues you automatically agree with our Comments Policy , Terms And Conditions and Privacy Policy .

Similar News